ERBB2 D769H

CI-VAR-00000532Explore in graph →NP_001276866.1:p.Asp769HisNM_001289937.1:c.2305G>CClinVar 375991 CIViC 35 rs121913468

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma1
ERBB2 D769H	Chemotherapy	Predictive	C	Supports Sensitivity Response	3	submitted	EID11499 Variant found in a patient that was diagnosed with muscle-invasive bladder cancer in pretreatment transurethral resection tumor samples (Fig. 1; Patients ID:CF3097). The patient was categorised as a “… (full text at CIViC) PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC	civic
Malignant Breast Neoplasm1
ERBB2 D769H	Lapatinib + NeratinibSubstitutes	Predictive	D	Supports Sensitivity Response	4	accepted	EID279 In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib. PMID 23220880 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Unmapped disease1unmapped disease
ERBB2 D769H	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID10024 A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC	civic